Eubel Brady & Suttman Asset Management Inc Bristol Myers Squibb CO Transaction History

Eubel Brady & Suttman Asset Management Inc

$766 Million
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	BUY	$53.63 - $62.52 $177,086 - $206,441	3,302 New	3,302 $206,000
Q3 2021 Nov 05, 2021	SELL	$59.17 - $69.31 $266,442 - $312,102	-4,503 Closed	0 $0
Q2 2021 Aug 17, 2021	SELL	$61.91 - $67.42 $278,780 - $303,592	-4,503 Reduced 50.0%	4,503 $284,000
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $290,944 - $327,226	4,903 Added 119.5%	9,006 $568,000
Q3 2020 Nov 12, 2020	BUY	$57.43 - $63.64 $13,553 - $15,019	236 Added 6.1%	4,103 $247,000
Q1 2020 May 13, 2020	BUY	$46.4 - $67.43 $179,428 - $260,751	3,867 New	3,867 $216,000
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $179,442 - $213,962	-3,977 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $35,371 - $44,086	-700 Reduced 14.97%	3,977 $220,000
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $68,608 - $78,982	-1,145 Reduced 19.67%	4,677 $296,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,822	5,822 $324,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.46B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.7 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.01 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.28 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.43 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.47 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $121B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eubel Brady & Suttman Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eubel Brady & Suttman Asset Management Inc with notifications on news.

Account